The clinical significance of HOXC10 in NSCLC was further supported by two recent studies that relate elevated HOXC10 expression to poor prognosis and disruption of epigenetic staging in NSCLC [29, 30]. This evidence concerns the gene HOXC10 and non-small cell lung carcinoma.